Amgen, Inc. (AMGN) Stock Price Today
Aura AI Summary
Key Stats
- $233.78BMarket Cap
- -Volume
- HealthSector
- $443.8452W High
- $271.1852W Low
- -Typical Hold Time
- $277.10BEnterprise Value
- 2.33%Div Yield
- -Trading Activity
Track Amgen, Inc. (AMGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amgen, Inc. has traded between a low of $271.18 and a high of $443.84, highlighting its annual price range. Buy and sell Amgen, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Most Recent News
SoFi Tech Solutions aims to be the AWS of finance with flexible fintech services under new president.
Kathleen Pierce-Gilmore, newly appointed president of SoFi Technology Solutions, is steering the company to become the "AWS of financial solutions" by offering modular fintech infrastructure tailored to diverse client needs. SoFi provides banking, pa...
Qinghai-Xizang Railway marks 20 years of safe, high-altitude operations with advanced tech and climate adaptations
The Qinghai-Xizang Railway, spanning 1,956 km across the world's highest plateau, has safely operated for 20 years, handling 104 million passengers and 824 million tonnes of cargo. Key to its success are advanced train control systems adapted for har...
Repatha lowers death risk by 20% in high-risk patients without prior heart attack or stroke.
Amgen's Repatha (evolocumab) significantly reduced all-cause and cardiovascular death risk by 20% in over 12,000 high-risk patients without previous heart attack or stroke, according to the Phase 3 VESALIUS-CV trial. The benefit emerged after 1.5 yea...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.